HOME >> BIOLOGY >> NEWS
New drug lead fights bacteria that can be lethal by disrupting quorum sensing and biofilms

BUFFALO, N.Y. -- University at Buffalo scientists have discovered a promising new drug lead that works by inhibiting the sophisticated bacterial communication system called quorum sensing.

The new compound is active against Pseudomonas aeruginosa, the gram-negative infection that strikes -- and usually kills -- cystic fibrosis patients and many others whose immune systems are compromised. The bacteria, like many others that have been routinely treated by antibiotics, have developed strains that are antibiotic-resistant.

The compound and the method the UB scientists used to develop it are described in the current (January 25, 2003) issue of Chemistry & Biology. The research also is discussed in a second article in the "Previews" section of the journal.

A patent application has been filed on the method of synthesis and the compound.

"With this work, we have taken a critical step toward inhibiting quorum sensing for clinical applications," said Hiroaki Suga, Ph.D., UB associate professor of chemistry and corresponding author on the paper.

Quorum sensing is the process by which bacterial cells "sense" that their numbers have reached a certain level, Suga explained, so that they then can mount an effective attack. The process gets switched on, he said, in response to the autoinducers that accumulate in bacterial cells as they begin reproducing. Once the cells "sense" that a quorum has been reached, they begin to communicate, a process that in turn "throws the switch" for manufacturing virulence factors, such as biofilms.

These tough, layered, polysaccharide shells provide the bacteria with a nearly impenetrable, self-protective mechanism that makes it extremely difficult, and in some cases impossible, to fight with antibiotics.

"Underneath the protective biofilm, the cells are happily reproducing, damaging the tissue and producing toxins," said Suga.

Based on the structure of the quorum-sensing
'"/>

Contact: Ellen Goldbaum
goldbaum@buffalo.edu
716-645-5000 x1415
University at Buffalo
24-Jan-2003


Page: 1 2 3

Related biology news :

1. UGA receives $6.7 M grant that will add knowledge in fights against cancer, Parkinsons disease
2. Protein that fights bacteria and viruses cloned by Scripps scientists
3. Sepsis drug fights infection, decreases hospital care over two year study
4. Study of monkey species that fights off AIDS may lead to new treatments for humans
5. Six-week, six-shot regimen fights hayfever for more than one season
6. Bacterias natural foe fights drug-resistant infections
7. Tea fights cavities, reduces plaque
8. Genetically engineered poliovirus fights brain tumors
9. Decoy molecule that fights food poisoning might help defeat other toxins
10. Fat switch fights flab at the cellular level, Science authors report
11. Researchers find color sensitive atomic switch in bacteria

Post Your Comments:
(Date:6/23/2015)... GARDENS, Fla. , June 23, 2015 ... identity management and authentication solutions, today announced enhanced ... strong, multi-factor authentication solution.  The enhancements build ... use of the DigitalPersona Altus platform and ... reader compatibility. In today,s environment ...
(Date:6/17/2015)... GERMANTOWN, Maryland , June 17, 2015 /PRNewswire/ ...   Produktlinie mit DNA-Tests verbessert den Analyseprozess und senkt ... ; Frankfurt Prime Standard: QIA) hat heute in den ... Investigator ® für die ... neuen Kits zur Erstellung genetischer Fingerabdrücke bieten eine integrierte ...
(Date:6/17/2015)... BEACH GARDENS, Fla. , June 17, 2015 ... management solutions, today announced that its U.are.U ® ... Togo,s Eateries, Inc., a ... fast casual sandwich chain, to increase security, improve ... Crossmatch fingerprint readers enable instant, non-repudiable identity confirmation ...
Breaking Biology News(10 mins):Crossmatch Releases Enhanced DigitalPersona Altus Advanced Authentication Functionality 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 3QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 4QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 5QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 6Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 2Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 3
(Date:7/2/2015)... ... July 02, 2015 , ... ... of surgical instruments in Orthopedics, announced today the acquisition of Turner Medical, ... largest provider of surgical instruments to the Spine Industry. The acquisition of Turner ...
(Date:7/1/2015)... BURLINGTON, Mass. , July 1, 2015 /PRNewswire/ ... three most frequently cited advantages of Otezla are ... favorable safety profile, as reported by surveyed rheumatologists. ... and launched for the treatment of active psoriatic ... . The current standard of care includes conventional ...
(Date:7/1/2015)... July 1, 2015   Neuraltus Pharmaceuticals, Inc. ... of groundbreaking drugs to treat neurodegenerative diseases such ... Robert G. Miller , M.D., Director of the ... California Pacific Medical Center in San Francisco, has been ... $1.5 million to help fund a Phase 2 ...
(Date:7/1/2015)... ... July 01, 2015 , ... A newly launched business ... to lower the barriers to innovation in life sciences R&D. The Pistoia Alliance President’s ... cash prizes of US$15,000 and a period of expert mentorship from a senior industry ...
Breaking Biology Technology:In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 3Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4Pistoia Alliance Launches Startup Challenge 2Pistoia Alliance Launches Startup Challenge 3
Cached News: